TY - JOUR
T1 - Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis
T2 - A Multicenter Experience
AU - Berinstein, Jeffrey A.
AU - Karl, Taylor
AU - Patel, Anish
AU - Dolinger, Michael
AU - Barrett, Terrence A.
AU - Ahmed, Waseem
AU - Click, Ben
AU - Steiner, Calen A.
AU - Dulaney, David
AU - Levine, Jake
AU - Hassan, Syed Adeel
AU - Perry, Courtney
AU - Flomenhoft, Deborah
AU - Ungaro, Ryan C.
AU - Berinstein, Elliot M.
AU - Sheehan, Jessica
AU - Cohen-Mekelburg, Shirley
AU - Regal, Randolph E.
AU - Stidham, Ryan W.
AU - Bishu, Shrinivas
AU - Colombel, Jean Frederic
AU - Higgins, Peter D.R.
N1 - Publisher Copyright:
Copyright © 2024 by The American College of Gastroenterology.
PY - 2024/7/1
Y1 - 2024/7/1
N2 - INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.
AB - INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.
KW - Janus kinase inhibitors
KW - acute severe ulcerative colitis
KW - ulcerative colitis
KW - upadacitinib
UR - http://www.scopus.com/inward/record.url?scp=85191815005&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000002674
DO - 10.14309/ajg.0000000000002674
M3 - Article
C2 - 38275248
AN - SCOPUS:85191815005
SN - 0002-9270
VL - 119
SP - 1421
EP - 1425
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 7
ER -